Vaxcyte PCVX
NASDAQ PCVX
$56.69 -1.58 (-2.71%)
At close: Sep 29, 2026 · 4:00 PM EDT

Vaxcyte (PCVX) Receivables - Accured (2022 - 2025)

Updated

Vaxcyte (PCVX) recorded Receivables - Accured of $21.36 million in Q4 2025, up 5.4% from $20.26 million a year earlier.

Analysis

Vaxcyte (PCVX) Receivables - Accured (2022 - 2025) Analysis & Trends

Starting with Q4 2022, Vaxcyte's Receivables - Accured history includes 8 quarters.

  • Annual Receivables - Accured has increased for three straight years, with a three-year compound annual growth rate of 95.7% (FY2022 to FY2025).
  • Across earlier years, Receivables - Accured came in at $20.26 million in FY2024 (+463.1%), $3.6 million in FY2023 (+26.3%) and $2.85 million in FY2022.
  • The Q4 2025 figure is the highest quarterly Receivables - Accured in data going back to Q4 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables - Accured (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn -
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn -
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn -
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn -
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn -
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn -
10 Vaxcyte 8.44 Bn 8.44 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 21.36 Mn
Dec 31, 2024 20.26 Mn
Sep 30, 2024 17.57 Mn
Jun 30, 2024 8.08 Mn
Mar 31, 2024 8.02 Mn
Dec 31, 2023 3.60 Mn
Sep 30, 2023 3.44 Mn
Dec 31, 2022 2.85 Mn
API Access

Vaxcyte Receivables - Accured API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-accured&ticker=PCVX&period=max&api_key=YOUR_API_KEY